News & Events

Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination

Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC

FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC

FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC

KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors

Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation

Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC

Astellas begins Phase III trial of setidegrasib in KRAS G12D mutated advanced lung cancer

Astellas begins Phase III trial of setidegrasib in KRAS G12D mutated advanced lung cancer